Pulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth Conference
Pulmonx (Nasdaq: LUNG), a global leader in minimally invasive treatments for severe lung disease, has announced its participation in the Lake Street 8th Annual Best Ideas Growth Conference. The event is scheduled to take place on Thursday, September 14, 2024, in New York.
Pulmonx representatives will be engaging in investor meetings during the conference, providing an opportunity for the company to showcase its innovations and growth strategies in the field of lung disease treatment. This participation underscores Pulmonx's commitment to engaging with investors and sharing insights about its market position and future prospects.
Pulmonx (Nasdaq: LUNG), un leader globale nel trattamento minimamente invasivo delle malattie polmonari gravi, ha annunciato la sua partecipazione alla 8ª Conferenza Annuale Best Ideas di Lake Street. L'evento è programmato per giovedì 14 settembre 2024, a New York.
I rappresentanti di Pulmonx parteciperanno a incontri con gli investitori durante la conferenza, offrendo l'opportunità all'azienda di presentare le sue innovazioni e strategie di crescita nel campo del trattamento delle malattie polmonari. Questa partecipazione sottolinea l'impegno di Pulmonx nel dialogare con gli investitori e condividere approfondimenti sulla propria posizione di mercato e prospettive future.
Pulmonx (Nasdaq: LUNG), un líder global en tratamientos mínimamente invasivos para enfermedades pulmonares severas, ha anunciado su participación en la 8ª Conferencia Anual de Mejores Ideas de Lake Street. El evento está programado para el jueves 14 de septiembre de 2024, en Nueva York.
Los representantes de Pulmonx se reunirán en reuniones con inversores durante la conferencia, brindando una oportunidad a la empresa para mostrar sus innovaciones y estrategias de crecimiento en el campo del tratamiento de enfermedades pulmonares. Esta participación subraya el compromiso de Pulmonx de interactuar con los inversores y compartir información sobre su posición en el mercado y perspectivas futuras.
Pulmonx (Nasdaq: LUNG)는 중증 폐질환을 위한 최소 침습 치료의 글로벌 리더로서 레이크 스트리트 제8회 연례 베스트 아이디어 성장 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 14일 목요일에 뉴욕에서 개최될 예정입니다.
Pulmonx의 대표들은 컨퍼런스 기간 동안 투자자 회의에 참여하여 회사의 혁신 및 폐질환 치료 분야의 성장 전략을 보여줄 기회를 제공합니다. 이번 참여는 Pulmonx가 투자자와의 소통에 대한 의지를 강조하며 시장 위치와 미래 전망에 대한 통찰을 공유하는 것을 나타냅니다.
Pulmonx (Nasdaq: LUNG), un leader mondial dans les traitements peu invasifs des maladies pulmonaires sévères, a annoncé sa participation à la 8ème Conférence Annuelle des Meilleures Idées de Lake Street. L'événement se déroulera le jeudi 14 septembre 2024, à New York.
Les représentants de Pulmonx participeront à des réunions avec des investisseurs durant la conférence, offrant à l'entreprise l'opportunité de présenter ses innovations et ses stratégies de croissance dans le domaine du traitement des maladies pulmonaires. Cette participation souligne l'engagement de Pulmonx à dialoguer avec les investisseurs et à partager des informations sur sa position sur le marché et ses perspectives d'avenir.
Pulmonx (Nasdaq: LUNG), ein weltweit führendes Unternehmen in der minimal-invasiven Behandlung schwerer Lungenkrankheiten, hat seine Teilnahme an der 8. jährlichen Best Ideas Growth Conference von Lake Street angekündigt. Die Veranstaltung findet am Donnerstag, den 14. September 2024, in New York statt.
Vertreter von Pulmonx werden während der Konferenz an Investorenmeetings teilnehmen, was der Firma die Gelegenheit bietet, ihre Innovationen und Wachstumsstrategien im Bereich der Behandlung von Lungenkrankheiten vorzustellen. Diese Teilnahme unterstreicht das Engagement von Pulmonx, mit Investoren in Kontakt zu treten und Einblicke in seine Marktposition und zukünftigen Perspektiven zu teilen.
- None.
- None.
REDWOOD CITY, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in investor meetings at the Lake Street 8th Annual Best Ideas Growth Conference in New York on Thursday, September 14, 2024.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
FAQ
When is Pulmonx (LUNG) participating in the Lake Street Best Ideas Growth Conference?
What type of meetings will Pulmonx (LUNG) be involved in at the conference?
What is Pulmonx's (LUNG) main focus as a company?
Where is the Lake Street Best Ideas Growth Conference being held in 2024?
